ARCHIVES

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

This article is from The Cancer Letter archive.

Vol. 06 No. 44 | November 7, 1980

Download PDF Visit The Full Archive

Related Articles

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001

Scientists Defend NCI, Criticize Post Series As Inaccurate

November 20, 1981

American Legacy Foundation Says Group is Fighting For Its Survival.

January 7, 2005

Adjuvant Chemo Improves Survival In Early Lung Cancer

July 30, 2004

Intense Therapies Better Than Lower Dose For AML

November 26, 2004

Foundation Honors Three In Oncology; Society Wins Software Grant From Microsoft.

October 26, 2001